Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03276884 · ClinicalTrials.gov registry record · NA
Growth and Tolerance of Young Infants
A NA study, sponsored by Abbott Nutrition.
- Completed
- Registry status
- NA
- Development phase
- 267
- Enrollment target
NCT03276884: Completed NA study, sponsored by Abbott Nutrition.
NCT03276884 is a NA study that has completed, run by Abbott Nutrition. The registered enrollment target is 267 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03276884, a NA study, has completed, sponsored by Abbott Nutrition.
- COMPLETED
- Registry status
- NA
- Development phase
- 267 participants
- Enrollment target
Study Summary
To compare growth and tolerance of healthy term infants fed two amino acid-based infant formulas.
Primary Outcome
Infant scale
Interventions
- OTHER Experimental Infant Formula
- OTHER Control Infant Formula
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 267 participants |
| Start Date | 2017-10-11 |
| Est. Completion | 2018-11-08 |
| Phase | NA |
What the finished NCT03276884 record still lists
NCT03276884 is an interventional study that assigns participants to a tested intervention. The registered 267 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 2 interventions - of which Experimental Infant Formula is the first listed.
NCT03276884 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03276884 about?
NCT03276884 is a clinical study titled "Growth and Tolerance of Young Infants". To compare growth and tolerance of healthy term infants fed two amino acid-based infant formulas.
What is the current status of trial NCT03276884?
This trial is currently completed. It is a NA study. The enrollment target is 267 participants. The study started on 2017-10-11. Estimated completion is 2018-11-08.
What interventions are being tested in trial NCT03276884?
The interventions under investigation include: Experimental Infant Formula (OTHER), Control Infant Formula (OTHER).
Who is sponsoring clinical trial NCT03276884?
This trial is sponsored by Abbott Nutrition, which has 89 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03276884's enrollment target sits among peer trials
267 395th of 2000 higher than 1,606 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04997109 · 267 participants · NA
Telemedicine in Early Childhood Constraint Therapy in Cerebral Palsy
- NCT05355701 · 267 participants · Phase 1
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
- NCT06203509 · 267 participants · NA
Improving Care Transitions for Medicaid Insured Individuals With Co-occurring Serious Mental Illness
- NCT05000632 · 268 participants · NA
Smoke Free SafeCare: Establishing a Smoke Free Home in CPS-involved Families
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI